Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000613:Aminobutyrates / Q000031:analogs & derivatives*; D003080:Cold Temperature; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications; D009125:Muscle Relaxants, Central / Q000627:therapeutic use*; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000503:physiopathology; D009442:Neurilemmoma / Q000601:surgery; D010264:Paraplegia / Q000150:complications; D010524:Peripheral Nervous System Neoplasms / Q000601:surgery; D011183:Postoperative Complications; D011782:Quadriplegia / Q000150:complications; D012026:Reflex, Stretch; D013119:Spinal Cord Injuries / Q000150:complications; D013125:Spinal Neoplasms / Q000150:complications; D013997:Time Factors; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000097:blood / Q000134:cerebrospinal fluid / Q000627:therapeutic use
D000613:Aminobutyrates; D009125:Muscle Relaxants, Central; D005680:gamma-Aminobutyric Acid